- Home
- ALLY vs EXEL Comparison
ALLY vs EXEL Comparison
Compare ALLY & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLY
- EXEL
- Stock Information
- Founded
- ALLY 1919
- EXEL 1994
- Country
- ALLY United States
- EXEL United States
- Employees
- ALLY N/A
- EXEL N/A
- Industry
- ALLY Major Banks
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLY Finance
- EXEL Health Care
- Exchange
- ALLY Nasdaq
- EXEL Nasdaq
- Market Cap
- ALLY 12.9B
- EXEL 10.4B
- IPO Year
- ALLY 2014
- EXEL 2000
- Fundamental
- Price
- ALLY $39.08
- EXEL $40.69
- Analyst Decision
- ALLY Buy
- EXEL Buy
- Analyst Count
- ALLY 17
- EXEL 24
- Target Price
- ALLY $46.33
- EXEL $44.73
- AVG Volume (30 Days)
- ALLY 3.6M
- EXEL 3.2M
- Earning Date
- ALLY 10-17-2025
- EXEL 11-04-2025
- Dividend Yield
- ALLY 3.06%
- EXEL N/A
- EPS Growth
- ALLY 11.52
- EXEL 53.55
- EPS
- ALLY 1.67
- EXEL 2.38
- Revenue
- ALLY $7,171,000,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- ALLY $20.35
- EXEL $9.14
- Revenue Next Year
- ALLY $14.10
- EXEL $12.51
- P/E Ratio
- ALLY $23.54
- EXEL $17.17
- Revenue Growth
- ALLY 6.02
- EXEL 9.93
- 52 Week Low
- ALLY $29.52
- EXEL $31.90
- 52 Week High
- ALLY $44.83
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- ALLY 45.01
- EXEL 58.21
- Support Level
- ALLY $38.23
- EXEL $36.00
- Resistance Level
- ALLY $40.32
- EXEL $41.55
- Average True Range (ATR)
- ALLY 1.15
- EXEL 1.39
- MACD
- ALLY -0.13
- EXEL 0.27
- Stochastic Oscillator
- ALLY 23.45
- EXEL 87.63
About ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.